2023 World Conference on Lung Cancer (Posters)-EP06.02. PD-L1 Expressions in Non-small Cell Lung Cancer and its Correlation with Imaging Findings

EP06.02. PD-L1 Expressions in Non-small Cell Lung Cancer and its Correlation with Imaging Findings - PDF(Abstract)

Pdf Summary

In this study, the authors aimed to determine the correlation between PD-L1 expression and imaging findings in patients with non-small cell lung cancer (NSCLC). PD-L1 expression is known to be a predictive biomarker for the response to immune checkpoint inhibitors (ICIs) used in the treatment of NSCLC. However, the relationship between PD-L1 expression and imaging features, such as consolidation tumor ratio (CTR), is not fully understood. <br /><br />The study included 239 patients with NSCLC who underwent surgery between May and December 2022. All patients underwent preoperative thin-section computed tomography (CT) scans. PD-L1 status was assessed using immunohistochemistry of tumor cells on tissue microarrays. <br /><br />The results showed that PD-L1 positivity was significantly associated with consolidation size, mediastinal diameter, CTR, tumor disappearance rate (TDR), and standardized uptake value (SUV) max value in 18F-FDG-PET/CT scans. PD-L1 positivity was not associated with tumor size. <br /><br />In multivariate analysis, tumors with higher CTR and larger SUV max values were more likely to be PD-L1 positive. This finding suggests that PD-L1 expression in surgically resected NSCLC is associated with specific imaging features. <br /><br />The authors believe that this information could be useful in selecting patients for induction therapy, including ICIs, in the future. This study provides valuable insights into the correlation between PD-L1 expression and imaging findings, which could help guide treatment strategies for NSCLC patients.

Asset Subtitle

Naoko Shigeta

Meta Tag

Speaker Naoko Shigeta

Topic Pathology & Biomarkers: Biomarkers for Immuno-oncology

Keywords

PD-L1 expression

imaging findings

non-small cell lung cancer

NSCLC

predictive biomarker

immune checkpoint inhibitors

consolidation tumor ratio

CTR

tumor disappearance rate

SUV max value